FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

New combos of old drugs may be boon to biotech

Tools

New York Times scribe Andrew Pollack takes a careful look at the current trend of making new drugs out of combinations of old therapies. Despite reporting one trial failure last week, CombinatoRx is out in the lead on this one. Researchers at the company are systematically running through the possible combinations of 2,000 generic drugs. But Pozen, Orexigen and other biotechs have combinatorial programs in place as well.

- read the article from The New York Times

Related Articles:
FDA buoys Pozen, accepts of amended response. Report
Orexigen Therapeutics files $86 million IPO. Report

More stories about FDA   Combinatorx   Pozen   Biotech IPO   New Drugs   Generics  

Comments

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.